Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Adam Foley-Comer"'
Autor:
Ewa Cendrowicz, Lisa Jacob, Shirley Greenwald, Ami Tamir, Iris Pecker, Rinat Tabakman, Lucy Ghantous, Liat Tamir, Roy Kahn, Jasmine Avichzer, Alexandra Aronin, Shira Amsili, Elina Zorde-Khvalevsky, Yosi Gozlan, Martijn Vlaming, Gerwin Huls, Tom van Meerten, Michal Elhalel Dranitzki, Adam Foley-Comer, Yaron Pereg, Amnon Peled, Ayelet Chajut, Edwin Bremer
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-16 (2022)
Abstract Background Treatment of Diffuse Large B Cell Lymphoma (DLBCL) patients with rituximab and the CHOP treatment regimen is associated with frequent intrinsic and acquired resistance. However, treatment with a CD47 monoclonal antibody in combina
Externí odkaz:
https://doaj.org/article/88f427a2882642b7b2f32986f378f0e2
Autor:
Shirley Greenwald, Ayelet Chajut, Alexandra Aronin, Amnon Peled, Matthew Weber, Ami Tamir, Iris Pecker, Rinat Tabakman, Lucy Ganthous, Liat Tamir, Roy Kahn, Jasmine Avichzer, Elina Zorde-Khvalevsky, Michal Michal Elhalel Dranitzki, Adam Foley-Comer, Mark Tykocinski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/9d1d813fb3514e5b91af359675727c2a
Autor:
Matthew P. Weber, Elina Zorde-Khvalevsky, Amnon Peled, Adam Foley-Comer, Ami Tamir, Ayelet Chajut, Lucy Ganthous, Alexandra Aronin, Rinat Tabakman, Shirley Greenwald, Jasmine Avichzer, Roy Kahn, Mark L. Tykocinski, Iris Pecker, Liat Ben Gigi Tamir, Michal Michal Elhalel Dranitzki
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTIGIT, an inhibitory immune checkpoint, is a target of interest for immuno-oncology combination therapies. TIGIT is part of a complex molecular network containing four receptors (DNAM1, TIGIT, PVRIG and CD96) and two ligands (PVR and PVRL2)
Autor:
Jason J. Luke, Anwaar Saeed, Babar Bashir, Yaffa Shwartz, Rinat Tabakman, Adam Foley-Comer, Antonio Jimeno
Publikováno v:
Journal of Clinical Oncology. 40:2647-2647
2647 Background: DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL. The SIRPα arm targets CD47 overexpressed on tumor cells, blocking the “don’t eat me” checkpoint and
Autor:
Osnat Bohana-Kashtan, Margaret M. Showel, Martin S. Tallman, Jessica K. Altman, Abi Vainstein-Haras, James M. Foran, Avichai Shimoni, Arnon Aharon, Michal Abraham, Yaron Pereg, Shaul Kadosh, Arnon Nagler, Ella Sorani, Yishai Ofran, Galia Oberkovitz, Naveen Pemmaraju, Amnon Peled, Ahmed AlRawi, Emil Samara, Geoffrey L. Uy, Tzipi Lustig, Michael Andreeff, Irit Glicko-Kabir, Stephen Shaw, Jorge E. Cortes, Carlos E. Bueso-Ramos, Adam Foley-Comer, Gautam Borthakur, John F. DiPersio, Jacob M. Rowe
Publikováno v:
CancerReferences. 127(8)
Background CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high-affinity CXCR4 antagonist BL-8040 with high-
Autor:
Amnon Peled, Ami Tamir, Ayelet Chajut, Ewa Cendrowicz, Yaron Pereg, Edwin Bremer, Lisa Jacob, Gerwin Huls, Shirley Greenwald, Yosi Gozlan, Adam Foley-Comer
Publikováno v:
Blood. 136:19-20
The mainstay of treatment for Diffuse Large B cell Lymphoma (DLBCL) is conventional chemotherapy combined with anti-CD20 monoclonal antibody rituximab (RTX). However, a subset of patients is refractory to treatment and between 20 to 50% of patients w
Autor:
Ami Tamir, Adam Foley-Comer, Michal Dranitzki-Elhalel, Yaron Pereg, Shira Amsili, Amnon Peled, Alexandra Aronin, Shirley Greenwald, Ayelet Chajut, Liat Ben-gigi-Tamir, Susan Hilgendorf, Yehudith Sagiv, Iris Pecker, Yosi Gozlan, Edwin Bremer
Publikováno v:
Cancer Immunology Research. 7:A076-A076
Background: The (re)activation of anticancer innate and adaptive immunity is at the forefront of developments in cancer therapy. Here, we report on a new immunotherapeutic fusion protein, termed Dual Signaling Protein 107 (DSP107). DSP107 was designe
Autor:
Jessica K. Altman, Olga Frankfurt, Martin S. Tallman, Arnon Aharon, Teresa McQueen, Jacob M. Rowe, Yishai Ofran, Yaron Pereg, Carlos E. Bueso-Ramos, Irit Avivi, Arnon Nagler, Michael Andreeff, Lena Russovsky, Gautam Borthakur, Jorge E. Cortes, Amnon Peled, Naveen Pemmaraju, Adam Foley-Comer
Publikováno v:
Blood. 124:950-950
Background: The bone marrow (BM) niche protects Acute Myeloid Leukemia (AML) cells from chemotherapy. BM homing of AML cells is dependent on CXCR4 and its ligand CXCL12, and high levels of CXCR4 expression correlate with poor survival in AML patients
Publikováno v:
Journal of Clinical Lipidology. 4:216